eNUVIO Inc.

Kelly Mante

🇬🇧 United Kingdom

8.9

Reviewed: December 1, 2023

• - Medical Writing
• - 5 weeks October - November 2023
• - Biotech Company

The medical writing services provided were of top quality. The documents were clear, precise, and tailored to meet the specific requirements of our regulatory submissions. The team's expertise was evident throughout the process.

Woodrow Grant

🇰🇷 South Korea

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Phillip Waelchi Jr.

🇹🇷 Turkey

9.1

Reviewed: August 11, 2023

• - Clinical Data Management
• - 6 weeks June - July 2023
• - CRO

The data management services were delivered on time and with great accuracy. Collaboration with the team was smooth, and they were always available to address any concerns or questions we had. We were very satisfied with the outcome.

Roberta Haag

🇲🇽 Mexico

8.8

Reviewed: May 15, 2024

• - Companion Diagnostics Development
• - 16 weeks January - May 2024
• - Pharmaceutical Company

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.

Annie Oberbrunner

🇪🇸 Spain

5.8

Reviewed: April 5, 2024

• - Biostatistical Design
• - 6 weeks February - March 2024
• - Research Institution

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Jerome Hamill

🇳🇱 Netherlands

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Stuart Schiller

🇸🇦 Saudi Arabia

6.3

Reviewed: November 7, 2024

• - Stability Studies
• - 16 months July 2023 - November 2024
• - Pharmaceutical Company

The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.

James Rempel

🇰🇷 South Korea

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Rosemary Carter

🇨🇭 Switzerland

8.6

Reviewed: October 2, 2023

• - Patient Engagement
• - 8 weeks August - September 2023
• - Clinical Research Organization

The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.